Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11 β-Methyl-19-Nortestosterone-17 β-Dodecylcarbonate in Men

41Citations
Citations of this article
75Readers
Mendeley users who have this article in their library.

Abstract

Context 11β-Methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity. Objectives (i) Quantify 11β-MNT binding to androgen and progesterone receptors. (ii) Evaluate safety, tolerability, and serum gonadotropin and testosterone suppression by 11β-MNTDC in men. Design and Setting (i) In vitro receptor binding and transactivation studies and (ii) randomized, double-blind, placebo-controlled single-dose, dose-escalating phase I study at two academic medical centers. Participants and Intervention Twelve healthy male volunteers were randomized (five active, one placebo) to escalating single oral doses (100, 200, 400, and 800 mg) of 11β-MNTDC or placebo given with or without food. Main Outcome Measures (i) In vitro 11β-MNT/11β-MNTDC human receptor binding and transactivation and (ii) safety and tolerability, pharmacokinetics, and quantification of serum gonadotropin and testosterone concentrations for 24 hours following dosing. Results 11β-MNT avidly binds and activates human androgen and progesterone receptors, but 11β-MNTDC has minimal activity. Single oral doses of 11β-MNTDC were well tolerated without serious adverse events. Administration of 11β-MNTDC with food markedly increased average 11β-MNTDC and 11β-MNT serum concentrations (P < 0.001 for all doses) compared with fasting with a significant dose-related effect on average serum drug concentrations (P < 0.0001). The 200-, 400-, and 800-mg doses significantly suppressed average serum testosterone concentrations (P < 0.05). Conclusions A single, oral dose of 11β-MNTDC up to 800 mg administered with food is safe and well tolerated in healthy men. The active drug 11β-MNT has androgenic and progestational activity, rapidly suppresses serum testosterone, and is a promising candidate for an effective once-daily oral male hormonal contraceptive.

References Powered by Scopus

A critical evaluation of simple methods for the estimation of free testosterone in serum

3332Citations
N/AReaders
Get full text

Contraceptive failure in the United States

1107Citations
N/AReaders
Get full text

Intended and unintended pregnancies worldwide in 2012 and recent trends

727Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Testis-specific serine kinase protein family in male fertility and as targets for non-hormonal male contraception

46Citations
N/AReaders
Get full text

Update on Novel Hormonal and Nonhormonal Male Contraceptive Development

43Citations
N/AReaders
Get full text

Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men

35Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wu, S., Yuen, F., Swerdloff, R. S., Pak, Y., Thirumalai, A., Liu, P. Y., … Wang, C. (2018). Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11 β-Methyl-19-Nortestosterone-17 β-Dodecylcarbonate in Men. Journal of Clinical Endocrinology and Metabolism, 104(3), 629–638. https://doi.org/10.1210/jc.2018-01528

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

59%

Researcher 6

27%

Professor / Associate Prof. 2

9%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

60%

Nursing and Health Professions 4

16%

Agricultural and Biological Sciences 4

16%

Pharmacology, Toxicology and Pharmaceut... 2

8%

Article Metrics

Tooltip
Mentions
News Mentions: 3
Social Media
Shares, Likes & Comments: 13

Save time finding and organizing research with Mendeley

Sign up for free